With only $41 million in cash, Tvardi Therapeutics may need to raise additional funds within a one-year period. Click here to ...
For U.S. patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slows the decline in forced vital capacity (FVC), ...
The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis ...
For U.S. patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slows the decline in forced vital capacity (FVC), ...
The approval is the first in more than a decade for an idiopathic pulmonary fibrosis treatment. The FDA has approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of adults with ...
Jascayd is the first new IPF therapy approved in over 10 years, addressing a rare and serious disease with limited treatments. FDA approval was based on Phase III trials showing reduced FVC decline ...
Tivardi Therapeutics shares plunge after phase 2 trial setbacks for TTI-101 in pulmonary fibrosis. Read more here.
DelveInsight’s, “Idiopathic Pulmonary Fibrosis Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Idiopathic Pulmonary Fibrosis pipeline ...
Credit: Boehringer Ingelheim. Nerandomilast reduces the expression of pro-fibrotic growth factors and inflammatory cytokines, commonly overexpressed in IPF. Findings showed nerandomilast led to a ...
(MENAFN- GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Idiopathic Pulmonary Fibrosis pipeline constitutes 80+ key companies continuously working towards ...
What Is Jascayd, and Why Does It Matter? Jascayd (nerandomilast) is a new oral medicine approved to treat idiopathic pulmonary fibrosis (IPF) in adults. IPF is a rare and serious condition that causes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback